FGFR2 (M420I)
Sign in to save this workspaceFGFR2 · Variant type: point · HGVS: p.M420I
Drug response on this variant
| # | Drug | Inhibition on variant | Residual | KISS |
|---|---|---|---|---|
| 1 | Pemigatinib | 99.8% | 0.2% | 98.23 |
| 2 | Futibatinib | 98.9% | 1.1% | 98.48 |
| 3 | Infigratinib | 97.8% | 2.2% | 98.24 |
| 4 | Alpelisib | 96.8% | 3.2% | 97.22 |
| 5 | Vandetanib | 95.3% | 4.7% | 95.74 |
| 6 | Pralsetinib | 93.1% | 6.9% | 93.43 |
| 7 | Repotrectinib | 88.1% | 11.9% | 84.21 |
| 8 | Selpercatinib | 87.5% | 12.5% | 96.72 |
| 9 | Erdafitinib | 86.1% | 13.9% | 95.71 |
| 10 | Sunitinib | 84.0% | 16.0% | 91.73 |
| 11 | Deucravacitinib | 83.3% | 16.7% | 98.99 |
| 12 | Tenalisib | 82.2% | 17.8% | 97.98 |
| 13 | Erlotinib | 81.7% | 18.3% | 99.75 |
| 14 | Canertinib | 81.4% | 18.6% | 96.49 |
| 15 | Entrectinib | 80.3% | 19.7% | 93.69 |
| 16 | Fedratinib | 79.9% | 20.1% | 96.21 |
| 17 | Ripretinib | 79.7% | 20.3% | 92.95 |
| 18 | Defactinib | 75.1% | 24.9% | 92.68 |
| 19 | Pacritinib | 71.8% | 28.2% | 88.64 |
| 20 | Tepotinib | 70.8% | 29.2% | 99.75 |
| 21 | Tivozanib | 65.3% | 34.7% | 92.42 |
| 22 | Upadacitinib | 51.9% | 48.1% | 97.98 |
| 23 | Avapritinib | 50.6% | 49.4% | 97.73 |
| 24 | Gilteritinib | 50.6% | 49.4% | 88.97 |
| 25 | Pexidartinib | 50.2% | 49.8% | 99.49 |
Wild-type vs variant — drug response delta
Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).
| Drug | Variant inh | WT inh | Δ (variant − WT) |
|---|---|---|---|
| Pemigatinib | 99.8% | 98.7% | +1.1% |
| Futibatinib | 98.9% | 99.3% | -0.4% |
| Infigratinib | 97.8% | 98.8% | -1.0% |
| Alpelisib | 96.8% | 98.9% | -2.1% |
| Vandetanib | 95.3% | 90.8% | +4.5% |
| Pralsetinib | 93.1% | 93.2% | -0.1% |
| Repotrectinib | 88.1% | 79.8% | +8.3% |
| Selpercatinib | 87.5% | 95.0% | -7.5% |
| Erdafitinib | 86.1% | 99.0% | -12.9% |
| Sunitinib | 84.0% | — | — |
| Deucravacitinib | 83.3% | 92.5% | -9.2% |
| Tenalisib | 82.2% | 96.0% | -13.8% |
| Erlotinib | 81.7% | — | — |
| Canertinib | 81.4% | — | — |
| Entrectinib | 80.3% | 81.5% | -1.2% |
| Fedratinib | 79.9% | — | — |
| Ripretinib | 79.7% | 85.4% | -5.7% |
| Defactinib | 75.1% | — | — |
| Pacritinib | 71.8% | — | — |
| Tepotinib | 70.8% | — | — |
| Tivozanib | 65.3% | — | — |
| Upadacitinib | 51.9% | — | — |
| Avapritinib | 50.6% | — | — |
| Gilteritinib | 50.6% | — | — |
| Pexidartinib | 50.2% | — | — |
Cancer associations
| Cancer | Organ | Source |
|---|---|---|
| endometrial_carcinoma | Uterus | ref |
| carcinoma_liver | Liver | ref |
Annotations
Sign in to read and post annotations.
Loading…
Served from saifudeen2026@1.0.0 · API 0.1.0 · 40.6ms